Pharmaceuticals
Insilico Medicine Announces First-in-Human Study for Orally PHD Inhibitor ISM5411 for Inflammatory Bowel Disease (IBD)
* ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. * ISM5411 is Insilico Medicine's fifth AI-driven drug program to enter clinical trials, with the first dose of healthy subjects completed inAustralia. ...
2023-12-05 06:00
1934
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investiga...
2023-12-04 21:50
1413
Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis
CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first cl...
2023-12-04 21:13
1351
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt,Germany. Under the terms of the agreement, Merck will be granted an exclusive licens...
2023-12-04 21:05
1432
Crystal Pharmatech's CDMO Business Unit successfully passed the dual certification of GMP and GDP conducted by SGS
SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Recently, Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services (CFS) successfully obtained dual certification in Good Manufacturing Practices (GMP)[1] and Good Distribution Practices (GDP)[2] from SGS, an internationally recognized thi...
2023-12-04 21:00
1183
Latest Updates of Viva's Portfolio Companies
HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...
2023-12-04 17:55
1877
First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer
SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase III clinical study (JSKN003-302) of anti-HER2 bispecific antibody-drug conjugate JSKN003 for treatment of advanced HER2-low breast cancer. Breast cancer is ...
2023-12-04 14:51
1594
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
CAMBRIDGE, Mass., Dec. 3, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced today it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation. Lycia...
2023-12-04 13:19
1296
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program inthe Netherlands for its investigational positron emission tomography...
2023-12-04 13:00
1457
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -- Zetomipzomib demonstrated clinically meaningful renal responses with a favorable tolerability profile in an earlier Phase 2 trial -- -- Renal and autoimmune diseases are k...
2023-12-04 08:58
4290
The Shanghai Cooperation Organization Traditional Medicine Forum opened
NANCHANG, China, Dec. 1, 2023 /PRNewswire/ -- The Shanghai Cooperation Organization Traditional Medicine Forum opened in Ganjiang New District,Jiangxi Province on November 30, 2023, with the theme of "Inheritance and innovation, unity and cooperation, promoting high-quality development of traditi...
2023-12-01 17:49
2258
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
HONG KONG, Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...
2023-12-01 14:41
2152
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
ROCKVILLE, Md. and SUZHOU, China, Dec. 1, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-12-01 12:00
2352
CNN's 'Vital Signs' explores the prospects of phage therapy to treat drug-resistant superbugs
HONG KONG, Dec. 1, 2023 /PRNewswire/ -- Antibiotics have been hailed as a "miracle drug" since the discovery of penicillin in 1928, but now, more bacteria are developing resistance to antibiotics. In 2019, the United Nations estimated nearly 5 million deaths were associated with antimicrobial re...
2023-12-01 11:29
1874
Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis
--Clinically meaningful and statistically significant results demonstrated for primary endpoint and key secondary endpoints for the 12-week induction period-- --Etrasimod was well-tolerated and its safety profile was consistent with prior studies-- --Everest will advance the late-stage study as...
2023-12-01 07:33
2352
Bushu Pharma Recognized with Frost & Sullivan's 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing and Robust Supply Chain Solutions
Bushu Pharma produces high-quality pharmaceutical and medical devices with sophisticated quality control and supply chain management support that prioritizes customer value. SAN ANTONIO, Nov. 30, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the contract development and manufacturing...
2023-11-30 22:30
1606
Registrational Phase III CLARIFY trial in prostate cancer commences
SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its r...
2023-11-30 22:16
1471
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity's67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical re...
2023-11-30 21:59
1622
Innovent's MSCI ESG Rating Upgraded to A
ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-11-30 21:37
7265
Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement
Collaboration focused on novel target discovery in prostate cancer LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology ...
2023-11-30 20:00
1372
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Announcement of "Cyber Sousa Award" Winners of the 16th Xiamen International Animation Festival
[Picked up by 272 media titles]
2024-11-26 16:48
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
12324
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
8375
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8090
MMA SMARTIES Thailand 2024 - Celebrates Unparalleled Marketing Innovation and Excellence in Thailand
2024-11-23 11:00
7519
WeBank Powers Fusion Bank's Rapid Launch of a Next-Generation Core Banking System
2024-11-22 15:21
5841